BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35942041)

  • 1. Jetstream Atherectomy Followed by Paclitaxel-Coated Balloons versus Balloon Angioplasty Followed by Paclitaxel-Coated Balloons: Twelve-Month Exploratory Results of the Prospective Randomized JET-RANGER Study.
    Shammas NW; Purushottam B; Shammas WJ; Christensen L; Shammas G; Weakley D; Jones-Miller S;
    Vasc Health Risk Manag; 2022; 18():603-615. PubMed ID: 35942041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jetstream Atherectomy with Paclitaxel-Coated Balloons: Two-Year Outcome of the Prospective Randomized JET-RANGER Study.
    Shammas NW; Shammas G; Christensen L; Jones-Miller S;
    Vasc Health Risk Manag; 2023; 19():133-137. PubMed ID: 36936551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE).
    Shammas NW; Shammas GA; Jones-Miller S; Shammas WJ; Bou-Dargham B; Shammas AN; Banerjee S; Rachwan RJ; Daher GE
    Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):771-777. PubMed ID: 30420096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jetstream Atherectomy in Treating Femoropopliteal In-Stent Restenosis: Meta-Analysis of the JETSTREAM-ISR and JET-ISR Trials.
    Shammas NW; Jones-Miller S; Shammas GA; Shammas WJ
    J Invasive Cardiol; 2020 Aug; 32(8):289-294. PubMed ID: 32737264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
    Stavroulakis K; Schwindt A; Torsello G; Stachmann A; Hericks C; Bosiers MJ; Beropoulis E; Stahlhoff S; Bisdas T
    J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
    Zeller T; Langhoff R; Rocha-Singh KJ; Jaff MR; Blessing E; Amann-Vesti B; Krzanowski M; Peeters P; Scheinert D; Torsello G; Sixt S; Tepe G;
    Circ Cardiovasc Interv; 2017 Sep; 10(9):e004848. PubMed ID: 28916599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
    Laird JA; Schneider PA; Jaff MR; Brodmann M; Zeller T; Metzger DC; Krishnan P; Scheinert D; Micari A; Wang H; Masters M; Tepe G
    Circ Cardiovasc Interv; 2019 Jun; 12(6):e007702. PubMed ID: 31195825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis).
    Dippel EJ; Makam P; Kovach R; George JC; Patlola R; Metzger DC; Mena-Hurtado C; Beasley R; Soukas P; Colon-Hernandez PJ; Stark MA; Walker C;
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):92-101. PubMed ID: 25499305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JetStream Atherectomy for the Treatment of In-Stent Restenosis of the Femoropopliteal Segment: One-Year Results of the JET-ISR Study.
    Shammas NW; Petruzzi N; Henao S; Armstrong EJ; Shimshak T; Banerjee S; Latif F; Eaves B; Brothers T; Golzar J; Shammas GA; Jones-Miller S; Christensen L; Shammas WJ
    J Endovasc Ther; 2021 Feb; 28(1):107-116. PubMed ID: 32885736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Rotational Atherectomy Followed by Drug-coated Balloon Angioplasty for the Treatment of Femoropopliteal Lesions-Comparison with Sole Drug-coated Balloon Revascularization: Two-year Outcomes.
    Rodoplu O; Oztas DM; Meric M; Beyaz MO; Ulukan MO; Yildiz CE; Unal O; Ugurlucan M
    Ann Vasc Surg; 2021 May; 73():222-233. PubMed ID: 33359329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon.
    Sachar R; Soga Y; Ansari MM; Kozuki A; Lopez L; Brodmann M; Schroë H; Ramanath VS; Diaz-Cartelle J; Zeller T;
    JACC Cardiovasc Interv; 2021 May; 14(10):1123-1133. PubMed ID: 34016410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
    Giannopoulos S; Kokkinidis DG; Jawaid O; Behan S; Hossain P; Alvandi B; Foley TR; Singh GD; Waldo SW; Armstrong EJ
    Cardiovasc Revasc Med; 2020 Jun; 21(6):771-778. PubMed ID: 31761634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
    Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-Year Outcomes of Orbital Atherectomy Combined With Drug-Coated Balloon Angioplasty for Treatment of Heavily Calcified Femoropopliteal Lesions.
    Kokkinidis DG; Jawaid O; Cantu D; Martinsen BJ; Igyarto Z; Valle JA; Waldo SW; Armstrong EJ
    J Endovasc Ther; 2020 Jun; 27(3):492-501. PubMed ID: 32364000
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
    Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
    Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
    J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
    Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
    Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.